PPCB Share Price Performance
US$9.00
-32.92 (-78.53%)
Price US$9.00
Share PriceUS$9.00
PPCB Community Narratives
There are no narratives available yet.
Recent PPCB News & Updates
No updates
Propanc Biopharma, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.39
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 6.9%
Propanc Biopharma, Inc. Competitors
About PPCB
- Founded
- 2007
- Employees
- 2
- CEO
- WebsiteView website
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Australian Market Performance
- 7 Days: -0.4%
- 3 Months: 6.8%
- 1 Year: 13.2%
- Year to Date: 5.2%
The market has stayed flat over the 7 days. Meanwhile, the market is actually up 13% over the past year. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading